United States · Research & regulatory guide
The FDA–Ignite interview: from the 2010 discussion to digital campaign review
The FDA–Ignite discussion is a useful starting point for understanding why evidence, message design and regulatory process belong in the same campaign brief. Today’s reader needs to trace each decision from the historical question to a specific source and then to the relevant advertising channel.
About the historical material and this article
The contemporary company announcement was reviewed; the complete interview transcript has not been authenticated. Historical reporting below is followed by a new editorial workflow based on separately identified regulatory sources.
Former resource: FDA_Ignite_012810_Interview_Transcript.pdf
This article focuses on US federal sources. The linked frameworks retain their state-specific and product-specific limits. It provides general orientation, not campaign clearance or FDA endorsement.
What is documented about the interview
Historical reporting
An inVentiv Health announcement dated 9 February 2010 reports an interview between Ignite Health’s Fabio Gratton and FDA official Dr. Jean-Ah Kang. It describes a request for data to inform the agency’s consideration of internet and social media guidance and directs readers to FDASM for the transcript. The announcement also connects the discussion to the November 2009 public hearing.
That source establishes the reported participants, subject and publication context. It does not let us reconstruct every question or answer. The date-like string in the former filename is retained as a document identifier, not used to invent a separate verified interview date.
Sources: [1]
Turn a historical question into a source-backed decision
Regulatory process
Under 21 CFR 10.115, media interviews and press materials are outside the definition of guidance documents. Guidance does not itself create legally enforceable duties; the applicable statutes and regulations still govern. This distinction helps prevent a historical remark from becoming a present-day compliance rule in a creative brief.
Build a decision record with four fields: the proposed communication, the specific issue, the relevant source and the remaining uncertainty. For a brand post, the issue might be a benefit claim, risk visibility or who controls the content. Assign each question to the right reviewer rather than treating “FDA social media guidance” as one approval box.
Sources: [2]
Connect evidence to the actual format
Editorial workflow
A useful internal review pack places the claim and its evidence beside the final creative. Include the visible caption, crop, playback state, link destination and any alternative placement. A copy document alone can hide what the reader will actually encounter on a phone.
Short promotional messages need a format decision as well as a wording decision. The June 2014 character-space document remains draft guidance. Record that status when using it to examine a proposed short product message; distinguish its recommendations from the underlying advertising requirements.
For example, a team adapting a long webinar summary into a sponsored post can first identify which statements survive the edit and which qualifications disappear. If the meaning changes, return the new asset for substantive review. This is an editorial control, not a finding that a particular post is legally compliant.
Sources: [3]
Record who controls an interactive conversation
Draft guidance and editorial application
FDA’s January 2014 interactive-media draft discusses control and influence when identifying promotion for postmarketing submission. It remains a draft. Its scope should not be expanded into an unsupported statement that every independent comment is company advertising.
Create a responsibility map for the brand account, agency, contracted speaker and community team. Record who can write, edit, approve, pin, repost or remove material. Preserve the context around a proposed reply so the reviewer can see the question it answers. Give medical enquiries and possible safety reports a defined internal escalation path rather than improvising a public marketing response.
Sources: [4]
Keep submission separate from creative approval
Regulatory requirement and editorial application
For materials within its scope, 21 CFR 314.81(b)(3)(i) requires applicant submissions at initial dissemination of promotional labeling or initial publication of advertising. FDA’s FAQ distinguishes routine submission and advisory review from pre-approval, while identifying special situations that need advance submissions or other controls.
Put the applicable submission route, responsible person and required records in the launch plan. A calendar entry saying “send to FDA” is incomplete without the product’s application context and the relevant timing. Keep internal medical/legal approval, agency submission and permission to publish as separate recorded decisions.
Review checklist
Editorial recommendation
- Identify the exact message and placement before researching the rule.
- Record whether each source is regulation, final guidance, draft or historical reporting.
- Keep evidence beside the final creative, including mobile variants.
- Assign ownership for replies, medical enquiries and safety escalation.
- Document submission timing and reopen review after substantive edits.
Sources and status
Historical records establish context. Regulatory records support the scoped discussion above; draft recommendations and implementation limits are identified separately. Source dates and verification limits are retained below.
- FDA official calls for supporting data — Ignite Health interview announcement
Company announcement — 9 February 2010
Relevant passage: Interview participants, request for evidence and historical FDASM project
Company reporting, not an authenticated copy of the interview transcript.
- 21 CFR 10.115 — Good guidance practices
Relevant passage: Paragraphs (b)(3), (d), (f) and (g)
Distinguishes guidance from interviews and press materials and explains public participation. This is a process rule, not product-specific campaign clearance.
- FDA — Internet/Social Media Platforms with Character Space Limitations
Draft guidance — not for implementation
Relevant passage: Sections III–V; especially benefit and risk in each communication
Nonbinding draft recommendations, not a new exemption from advertising requirements. Status checked on the official record.
- FDA — Postmarketing Submissions of Interactive Promotional Media
Draft guidance — not for implementation
Relevant passage: Section IV — responsibility for promotional content; section V — submission recommendations
Draft criteria concern postmarketing submissions; do not interpret them as a complete rule for every comment, safety report or third-party interaction.
- 21 CFR 314.81(b)(3)(i) — Advertisements and promotional labeling
Relevant passage: Paragraph (b)(3)(i)
Application-holder reporting provision; submission is distinct from approval. Other application types and special pre-dissemination duties need their own review.
- OPDP Frequently Asked Questions
Relevant passage: Presentation of Information; Pre-distribution Submissions; FDA-Approved
Use the underlying rules and product-specific route; advisory comments and submission are distinct from product approval.